{"schema_version":"1.0","type":"article","title":"下一代世紀大藥的陰影？","url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.md","lang":"zh-Hant","date":"2026-05-07","publish_at":"2026-05-07T10:30:00+08:00","updated_at":"2026-05-07","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","CAR-T","RAS","ADC","CNS"],"summary":"【Pan-RAS 戰爭升級：Erasca 數據驚艷，卻撞上 Revolution 的專利戰與安全性陰影】📌 RAS 賽道，正在從「誰的療效更強」進入「誰能同時守住安全性、IP 與商業化窗口」的新階段。","key_points":[],"facts":[],"sections":["01｜Erasca 的 ERAS-0015：數據很亮，但亮得太有攻擊性","02｜Revolution 的反擊：不是只有數據之爭，而是專利、商業機密與宣傳口徑三線作戰","03｜患者死亡事件：安全性陰影為 ERAS-0015 的高光數據降溫","04｜RMC-6236 的一體兩面：療效建立標竿，毒性也留下超越窗口","05｜泛 RAS、泛 KRAS、突變選擇性：未來競爭不只比「誰更廣」","06｜誰會是 me-better？RAS 賽道會重演 EGFR、HER2 ADC 和 BCMA CAR-T 的歷史嗎？","07｜胰臟癌治療格局的改變台灣公司中槍？"],"references":[{"title":"[0]: 公開資料＆各公司官網","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"\"Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer","source":"Revolution Medicines\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"\"Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors – Erasca\"","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Erasca Stock Plummets After Patient Death Strikes Its Chance To Rival Revolution","source":"Investor's Business Daily","date":"","url":""},{"title":"Erasca stock crashed Tuesday after a patient in its pancreatic cancer study died following a bout of pneumonia.","source":"","date":"","url":""},{"title":"www.investors.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"8-K","source":"","date":"","url":""},{"title":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526179214/eras-20260427.htm","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526179214/eras-20260427.htm"},{"title":"www.sec.gov","source":"","date":"","url":""},{"title":"\"8-K\"","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"\"Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting","source":"Revolution Medicines\"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：下一代世紀大藥的陰影？","url":"https://drugnews.com.tw/assets/articles/pan-ras-patent-safety-war/dcard-01.webp"},{"alt":"Dcard 原圖：下一代世紀大藥的陰影？","url":"https://drugnews.com.tw/assets/articles/pan-ras-patent-safety-war/dcard-02.png"},{"alt":"Dcard 原圖：下一代世紀大藥的陰影？","url":"https://drugnews.com.tw/assets/articles/pan-ras-patent-safety-war/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pan-ras-patent-safety-war/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-07）。下一代世紀大藥的陰影？。https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-07-pan-ras-patent-safety-war-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}